Doc code. RCEX

Doc description: Request for Continued Examination (RCE)

X
Request for Continued Examination (RCE)
Us Page not Trademark Office Us CHRATHART CE COMMERCE
Us Page not Trademark Office Us CHRATHART CE COMMERCE
Under the Pagement Reduction Act of 1985, no present are request or recorded as addressed in hermality and recision and act of 1985, no present are request of recorded as addressed in hermality and recision and activities.

	REC	QUEST FO		ED EXAMINATION TO THE PROPERTY OF THE PROPERTY		SMITTAL			
Application Number	09698526	Fiting Date	2000-10-26	Docket Number (if applicable)	990301	Art Unit	2193		
First Named Inventor	Vassilovski et a	ıl.	***************************************	Examiner Name	Kang, Insun				
Request for C	ontinued Exerni	estion (RCE)	practice under 37	or 37 CFR 1.114 of the CFR 1.114 does not a this form is located at t	only to any utility or a	optication. plant application feed	prior to June 8,		
		5	SUBMISSION RE	QUIRED UNDER 3	7 CFR 1.114				
ensered, appli	were filed unless cant must reque	s applicant in st non-entry	structs otherwise of such amendmes		sh to have any prev	lously filed unentered	d artiendment(s)		
Previous!	y submitted, If a in even if this bo	final Office a ix is not chec	ction is outstandin ked.	g, any amendments file	d after the final Offic	re action may be con	sidered as a		
Co	nsider the argun	nents in the A	Appeal Brief or Rep	oly Brief previously (flec	l on		•		
OI	181		-						
⊠ Enclosed							***************************************		
⊠ Ar	nendmant/Reply								
inf	rmailion Disclos	iure Staleme	nt (IDS)						
☐ Aff	idavii(s.)/ Declara	stion(s)							
	her								
			M	ISCELLANEOUS	***************************************	***************************************	***************************************		
Suspensi (Period o	on of action on t f suspension sh	he above-ide all not excee	ntified application d 3 months; Fee o	is requested under 37 nder 37 CFR 1.17(i) re	CFR 1.103(c) for a quired)	period of months			
Other									
				FEES		***************************************	*******************************		
K) the Dire	ctor is hereby at	CFR 1.17(e) i nthorized to d 1.70026	s required by 37 harge any undurpa	CFR 1,114 when the B Byrnent of fees, or cred	RCE is filed. If any overpayments	i, to			
		SIGNATUR	RE OF APPLICA	NT, ATTORNEY, OF	AGENT REQUIR	RED			
	Practitioner Sign	nature					***************************************		
Applica	int Signature								
	***************************************	******************************							

Doc code: RCEX

Doc description: Request for Continued Examination (RCE)

PTO/\$8/36EFS (07-03) Approved for use traceing 07/31/2812, DMB 0651-631.
U.S. Pulans and Franceinsk Officer U.S. DEFANTIMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a coloration of information unless it contains a valid DMB control number.

	Signature of Registered U.S. Patent Practitioner								
-	Signature	Win Tag C	Date (YYYY-MM-DD)	2010-05-23					
-	Name	Won Tae Kim	Registration Number	40457					

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for raducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistence in completing the form, call 1-800-PTO-9199 and select option 2

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93.579) requires that you be given certain information in connection with your submission of like attached form rolated to a patient application or patent. Accordingly, pursuant to the reculirements of the Act, please be advised that: (1) the general submirphy for the collection of this information is 30 LS.C. 2(0)(2); (2) farnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to pricoses and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result intermination of proceedings or absandancement of the application or expression of the patient of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information
  Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552s). Records from this system of records may be disclosed to the
  Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a confractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 6 i U.S. C. 552a/m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be discossed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, furing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the imitations of 37 CFR 1.14, as a routine use, to the public after record was field in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.